ERBB2 and breast cancer: An ongoing prospective study assessing neoadjuvant chemoradiation therapy (NACRT), the Neo-APBI-01 trial (NCT02806258), was specifically designed for aggressive HER2-negative locally advanced BC, i.e., triple negative (TN) and luminal B (LB) subtypes.